Menu Search
Equities

Poltreg SA

PTG:WSE

Poltreg SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)54.60
  • Today's Change0.00 / 0.00%
  • Shares traded608.00
  • 1 Year change-10.78%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Poltreg SA had net income fall 588.92% from a loss of 1.97m to a larger loss of 13.55m despite a 40.04% increase in revenues from 999.00k to 1.40m. An increase in the cost of goods sold as a percentage of sales from 503.80% to 911.87% was a component in the falling net income despite rising revenues.
Gross margin-1,804.83%
Net profit margin-2,903.50%
Operating margin-3,246.83%
Return on assets-14.82%
Return on equity-19.79%
Return on investment-16.41%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Poltreg SA fell by 24.09m. Cash Flow from Financing totalled 20.77m or 1,484.70% of revenues. In addition the company used 13.28m for operations while cash used for investing totalled 31.57m.
Cash flow per share-3.34
Price/Cash flow per share--
Book value per share17.04
Tangible book value per share16.85
More ▼

Balance sheet in PLNView more

Poltreg SA appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.26% of the market capitalization can be attributed to its 65.95m and debt could be paid in full if management chose.
Current ratio4.25
Quick ratio4.21
Total debt/total equity0.1004
Total debt/total capital0.0913
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.